灯盏细辛注射液治疗急性缺血性卒中的系统评价  

Systematic review of Dengzhan Xixin Injection in treatment of acute ischemic stroke

作　　者：张晓朦[1] 吴嘉瑞[1] 张冰[1] 

机构地区：[1]北京中医药大学,北京100102

出　　处：《中华中医药杂志》2015年第7期2459-2463,共5页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家自然科学基金项目(No.81473547);北京市自然科学基金课题(No.7112075);北京市中医药科技发展基金课题(No.JJ-2010-70);北京中医药大学科研创新团队项目资助(No.2011-CXTD-14);北京中医药大学"重点学科"开放课题(No.2013-ZDXKKF-19);国家科技支撑计划课题(No.2007BAI10B01);北京中医药大学自主课题(No.2014-JYBZZ-XS-078)~~

摘　　要：目的:系统评价灯盏细辛注射液(DZXX)用于治疗急性缺血性卒中的有效性及安全性。方法:全面系统地检索中国期刊全文数据库(CNKI)、维普数据库(VIP)、万方数据库、中国生物医学文献数据库(CBM)、Pub Med、EMbase和Cochrane图书馆,纳入符合标准的随机或半随机对照试验。两名研究者独立采用Cochrane风险评价表评价纳入研究的质量,并提取所需资料通过Rev Man 5.2软件进行Meta分析。结果:共纳入14篇研究,共1 454例受试者。文献质量较好。Meta分析的结果显示,在西医常规治疗(WM)基础上,DZXX较复方丹参注射液(FD)治疗急性缺血性卒中能更好地提高临床疗效愈显率(RR=1.54,95%CI[1.39,1.71],P<0.00001),改善患者的神经功能缺损评分(M D=-4.22,95%CI[-5.65,-2.79],P<0.00001),改善血液流变学和血脂指标,如降低血浆黏度(MD=-0.44,95%CI[-0.68,-0.20],P=0.0003),降低血液中总胆固醇的含量(MD=-0.87,95%CI[-1.28,-0.47],P<0.0001)等。14篇研究报道了共计13例不良反应,但均未出现严重不良反应。结论:在WM基础上,DZXX较FD治疗急性缺血性卒中具有较好的疗效,其安全性仍需进一步探讨。Objective： To systematically evaluate the clinical efficacy and safety of Dengzhan Xixin Injection（DZXX） in treatment of acute ischemic stroke. Methods： Randomized controlled trials（RCTs） regarding DZXX in treatment of acute ischemic stroke were searched in China National Knowledge Infrastructure（CNKI）, VIP database, Wanfang database, Chinese Biomedical Literature database（CBM）, Pub Med, Embase and Cochrane Library. Two reviewers independently assessed the quality of the included studies by Cochrane risk of bias method, and extracted and analyzed necessary information for Meta analysis by Rev Man 5.2 software. Results： A total of 14 RCTs with 1 454 participants were included. The quality of the studies was generally good. The Meta analysis results indicated that based on the conventional treatment with western medicines（WM）, DZXX was more effective than Fufang Danshen Injection（FD） in the outcomes of markedly effective rate（RR=1.54, 95%CI[1.39, 1.71], P0.00001）, neurological deficit score（MD=-4.22, 95%CI[-5.65,-2.79], P0.00001）, and hemorheology and blood-fat index, such as plasma viscosity（MD=-0.44, 95%CI[-0.68,-0.20], P=0.0003）, total cholesterol（MD=-0.87, 95%CI[-1.28,-0.47], P0.0001）, etc. A total of 13 adverse reactions reported in the 14 included studies, and with no serious adverse reactions. Conclusion： Based on the conventional treatment with WM, DZXX is more effective than FD in the treatment of acute ischemic stroke, but the saftey still need to be further discussed.

关 键 词：灯盏细辛注射液 急性缺血性卒中 系统评价 

分 类 号：R277.7[医药卫生—中医学]